Cergutuzumab amunaleukin

Cergutuzumab amunaleukin (CEA-IL2v) is a monomeric carcinoembryonic antigen (CEA) -targeted IL-2 variant-based immunocytokine. Cergutuzumab amunaleukin has immunostimulating and antineoplastic activities[1].

Product Specifications

CAS Number

[1509916-03-3]

Product Name Alternative

CEA-IL2v; RG 7813; RO 6895882

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cergutuzumab-amunaleukin.html

Purity

99.5

Solubility

10 mM in DMSO

Smiles

[Cergutuzumabamunaleukin]

Molecular Weight

(162.05 kDa)

References & Citations

[1]Christian Klein, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017 Jan 11;6 (3) :e1277306.